Hemostatic and liver safety of ITA-LNPs. (A) Schematic of experiments testing ITA-LNP actions on platelets. (B) FACS histograms examining accumulation of ITA-LNPs in platelets after bolus injection in panel A. (C) FACS-based platelet activation assays in isolated platelets from experiments in panel A. (D) Bleeding assays in C57BL/6 mice after daily injections of ITA-LNPs (50 mg/kg), 100 μL PBS, or enoxaparin (1 mg/kg) for a total duration of 3 days. (E) Complete blood counts from blood samples obtained in panel D. (F) Hematoxylin and eosin staining in liver sections from C57BL/6 mice used in panel D. The images were taken at different magnification powers as indicated. active. PE, phosphatidylethanolamine; ANOVA, analysis of variance; ADP, adenosine 5′-diphosphate; FITC, fluorescein isothiocyanate; Max, maximum; neg., negative; NS, not significant; PBS, phosphate-buffered saline; pos., positive; SD, standard deviation; WT, wild type.
Figure 5.

Hemostatic and liver safety of ITA-LNPs. (A) Schematic of experiments testing ITA-LNP actions on platelets. (B) FACS histograms examining accumulation of ITA-LNPs in platelets after bolus injection in panel A. (C) FACS-based platelet activation assays in isolated platelets from experiments in panel A. (D) Bleeding assays in C57BL/6 mice after daily injections of ITA-LNPs (50 mg/kg), 100 μL PBS, or enoxaparin (1 mg/kg) for a total duration of 3 days. (E) Complete blood counts from blood samples obtained in panel D. (F) Hematoxylin and eosin staining in liver sections from C57BL/6 mice used in panel D. The images were taken at different magnification powers as indicated. active. PE, phosphatidylethanolamine; ANOVA, analysis of variance; ADP, adenosine 5′-diphosphate; FITC, fluorescein isothiocyanate; Max, maximum; neg., negative; NS, not significant; PBS, phosphate-buffered saline; pos., positive; SD, standard deviation; WT, wild type.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal